Program London

'Financing Science-Based start-Up Companies'

Thursday 14 December 2000
 

9.30    INTRODUCTION AND WELCOME

Rudy Dekeyser, Conference Chair of the first day

Vice President of ASTP and Technology Transfer Manager Flanders Interuniversity Institute for Biotechnology (VIB), Belgium

9.35 - 11.00 SCIENTIFIC FUNDING

Why do research institutes establish their own venture capital fund?

Technology provider:
David Owen, Chief Executive Officer MRC Technology United Kingdom, President of ASTP

Investor:
Philippe Deville, Chief Executive Officer of CD TECHNICOM and leader of the European Venture
Capital Association (EVCA) Entrepreneurship Task Force

11.00 - 11.30 COFFEE BREAK

11.30 - 13.00 EARLY STAGE FINANCING

Practices and pitfalls of finding outside investors

Technology provider:
Jonathan Gee, Chief Executive Imperial College Innovations, United Kingdom

Investor:
Simon Barnes, Atlas Ventures, United Kingdom

13.00 - 14.30 LUNCH

14.30 - 16.00 LATER STAGE INVESTMENT

Investment sources, methods of operation and exit strategies of growing companies

Technology provider:

Ton Logtenberg, Chief Scientific Officer of Crucell, who is now doing his IPO of Crucell in the Netherlands.
Investor:
Dr. Sam Williams, Senior Life Science Analyst, Robertson Stephens International

16.00 - 16.30 BREAK

16.30 - 17.15 PANEL DISCUSSION

Friday 15 December 2000
 

9.00    INTRODUCTION AND WELCOME

David Owen, Conference Chair of the second day
President of ASTP and Chief Executive Officer MRC Technology United Kingdom

9.05 - 10.30 CONTRACTS AND OTHER LEGAL ASPECTS

A closer look at the rights and obligation of founders, technology providers and investors

Technology Provider:
Dr. Teri Willey, Vice President ARCH Development Corporation, University of Chicago, USA and Past President AUTM

Investor:
Dr. Jeremy Reffin, Assistant Director, APAX Partners & Co. London, United Kingdom

10.30 - 11.00 COFFEE BREAK

11.00 - 12.30 TECHNOLOGY VALUATION

Approaches to determine the value of the technology and business plan and the translation of the value in equity and/or license provisions

Technology Provider:
Laurent Kott, Vice President for Technology Transfer, INRIA France

Investor:
David Brister, Director Medical Ventures Management, United Kingdom

12.30 - 14.00 LUNCH

14.00 - 15.00 INVOLVEMENT OF THE INSTITUTE AFTER THE INCORPORATION OF THE

START-UP
The role of the technology provider once the start-up has been founded

Technology Provider:
Ami Lowenstein, General Manager, Dimotech Ltd at Technion Israel Institute of Technology

Investor:
Dr. Magnus Persson, Partner of HealthCap Venture Capital Fund and Associate Professor at the Karolinska Institute, Sweden

15.00 - 15.30 BREAK

15.30 - 16.30 CLOSING SESSION
          Collected questions with panel of all speakers and concluding remarks